ONLINE SUBMISSION
  November, 2009

Pharmageddon ó a myth or reality

 
 


Since time immemorial health and illness are two sides of same coin revolving around medicine. Either it was the era of Thalidomide disaster which precipitated horrific congenital anomalies in newborns when used by pregnant mothers for their morning sickness1 or the present concept about Statins that it may work for the prophylaxis of heart ailments in everyone over 40,2 the safety and effectiveness of medicine is a question. Although on one hand the evidence of thalidomide utility in leukaemia and leprosy3 speaks volumes of proper usage of a threatened medicine while on the other hand change of statins status from prescription medicine to non-prescription medicine may increase the risk of interaction to adverse reactions in times of self medication.
Pharmageddon, a controversial concept, embraces the idea of "for every ill there is a pill". It is defined as the prospect of a world in which medicines and medicine produce more ill-health than health, and when medical progress does more harm than good.4 It is a vicious cycle mainly involving the pharmaceutical industry, physician and the patient.
Pharmaceutical industry boasts to cater to the needs of masses but always gives priority to profit maximization. New molecules are launched with a 'speed-to-market strategy'.5 To be precise pharmaceutical companies strictly abide to decades old statement of Milton Friedman that social responsibility of any business is to increase its profit.6 On the other hand physicians are the target of plethora of devious marketing strategies of pharmaceutical industries.7 Thus keeping in view the benefit-to-risk ratio only the physician is the balancing power to ascertain the true need of medicine and provide relief and succour to the patient in minimum time and cost.
Global warming and ozone depletion being interrelated paved the way for global climate change thus threatened to manifest new pathologies and disorders. In the same way unethical marketing of new chemical entities and their irrational and injudicious use may evolve into a fragile and ticklish blueprint of pharmageddon.
The probable prophylactic measure for pharmageddon is the rational attitude of physicians towards pharmaceutical industries which in turn will benefit the society in general and patient in particular.
Shazia Qasim Jamshed
Discipline of Social and Administrative Pharmacy,
School of Pharmaceutical Sciences Universiti Sains Malaysia,
Penang, Malaysia.


References

1.McBride WG. Thalidomide and congenital abnormalities. Lancet 1962; 2: 1358.
2.Smith R. Millions of statins will go to low-risk over 40s. (Online) 2009 Feb 10 (Cited 2009 May 15). Available from URL: http://www.telegraph.co.uk/health/healthnews/4573728/Millions-of-statins-will-go-to-low-risk-over-40s.html.
3.Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med 1999; 341: 1606-9.
4.This definition was agreed following a meeting on Pharmageddon, in London on 23 April 2007, attended by Professor Graham Dukes, Dr Andrew Herxheimer, Professor David Healy, Charles Medawar, Susan Powell, Dr Tim Reed and Donna Sharpe.
5.Kennedy T. Pharmaceutical Project Management. Drugs and Pharmaceutical Sciences Series 2008. Informa Healthcare, USA.
6.Milton F. "The Social Responsibility of Business is to Increase its Profits." The New York Times; September 13, 1970.
7.Iserson KV, Cerfolio RJ, Sade RM. Politely refuse the pen and note pad: gifts from industry to physicians harm patients. Ann Thorac Surg 2007; 84: 1077-84.


News & Events

Dear Friends and Colleagues,
May you have a very Happy EID with your friends and Family.
May all of us be Blessed with peace and tranquility.
Let us all jointly say a prayer for all troubled persons all over the world
Warm regards,
Dr. Fatema Jawad
Editor-in-chief,
Journal of Pakistan Medical Association, Karachi
President, PAME
Pakistan Association of Medical Editors



WHO/GOARN Request for technical assistance for Cholera Control in Northern Iraq

Request for assistance

WHO is requesting assistance from GOARN partners to identify the following cholera and diarrhoeal diseases expertise to support the Ministry of Health of Iraq in cholera risk assessment and immediate preparedness activities to improve the health outcomes of the Syrian refugees current living in camps in the Kurdistan region of Iraq.

  • two (2) epidemiologists
  • two (2) clinical management experts
  • one (1) environmental health expert (WATSAN)
  • one (1)laboratory expert

Duration

6 day mission starting 13 June 2014 (this excludes travel time).

Location

Northern Iraq (Kurdistan region).

Language requirements

All candidates must be fluent in English- written, spoken and comprehension. Fluency in Arabic is an asset. Knowledge, abilities and skills All candidates are expected to demonstrate the following

  • Ability to conceptualize and promote innovative strategies and policies.
  • Ability to communicate and write in a clear concise manner, and to develop effective guidelines.
  • Excellent negotiation and interpersonal skills complemented by ability to motivate and lead others and to promote consensus. Tact, discretion and diplomacy
  • Demonstrated ability for project appraisal, project management, monitoring and evaluation and project impact assessment.
  • Ability to work with host governments and their agents, INGOs and national NGOs an advantage.
  • Proven experience of managing a large workload and multiple priorities.
  • Ability to work in difficult conditions.

Support to the mission

WHO/GOARN will cover the travel and per diem (to cover daily expense in the field) expenses for the duration of their mission. GOARN missions do NOT offer salary, consultancy fees or any other form of remuneration.

WHO will provide appropriate logistics support for the field mission. Pre-deployment orientation/training may be required at WHO.

Partners offers of assistance

Partners are requested to reply with offers of assistance, together with CVs and details of the availability of staff for this mission by email to goarn@who.int latest by 30 May 2014. Details of all offers from partners and eventual deployments will be maintained on the GOARN SharePoint.

Operational Contacts

Mamunur Malik WHO EMRO malikm@who.int

William Perea WHO HQ pereaw@who.int

Patrick Drury GOARN druryp@who.int



News



Index



Supplement